Depression

From older age bipolar disorder to the relationship between antidepressants and emotional numbing, here are highlights from the week in Psychiatric Times.

As patients improve with antidepressant treatment, emotional numbing decreases.

A new—cough, cough—combination treatment for depression. Researchers performed an RCT of dextromethorphan-bupropion in major depressive disorder.

From historic USPSTF draft screening recommendations to the need for novel treatments for bipolar depression, here are highlights from the week in Psychiatric Times.

In this CME article, learn more about the rationale for considering novel treatments for patients with bipolar depression.

The experts weighed in on a wide variety of psychiatric issues for the August 2022 issue of Psychiatric Times.

What is the optimal dose of aripiprazole as augmentation for treatment-refractory depression? Researchers performed a systematic review and dose-effect meta-analysis.

In this CME article, examine how current DSM nosology defines the proper method of assessing a mixed-episode patient and which diagnostic labels to give them based on their presenting symptomatology.

Dextromethorphan HBr -bupropion HCl extended-release tablets for the treatment of major depressive disorder just became FDA approved.

Treating women of reproductive age who have depression can be difficult. Here’s an overview on the subject from the 2022 Annual Psychiatric Times™ World CME Conference.

What are the latest treatments in difficult to treat depression?

Is it prolonged grief or MDD? Expert shares insights at premiere annual meeting.

Further evidence-based antidepressant treatments are needed for children and adolescents with depression.

The SSRIs’ mechanism of action is no index of safety and efficacy.

A new review shows that there is no convincing evidence that depression is caused low levels of serotonin.

What are the biggest challenges facing both clinicians and patients, and how can we address them?

A psychiatrist lists the top 8 most pressing issues in MDD, from training to accessibility.

Adjunctive metformin in bipolar disorder. Researchers performed a randomized clinical trial of treating insulin resistance to improve clinical outcomes in treatment-resistant bipolar depression.

Zuranolone, an investigational oral drug being evaluated in women with postpartum depression, sees positive phase 3 study results.

Axsome Therapeutics announced the robust antidepressant efficacy demonstrated in this latest study.

Here’s why we should be paying special attention to women's depression treatment.

Recommendations are often vague, contradictory, according to investigators.

Home environments have a clear impact on depression treatment outcomes.

In this CME, review novel, currently available, and promising pharmacological treatment options for treatment-resistant depression.

Zuranolone, a drug for the treatment of major depressive disorder and postpartum disorder, is on a rolling submission of a new drug application.